Zhongao Biopharmaceutical Technology

Zhongao Biopharmaceutical Technology (Guangdong) Co., Ltd. is a clinical-stage biopharmaceutical company founded in 2018 by foreign Chinese scientists. Headquartered in Zhongshan, Guangdong, China, the company focuses on developing first-in-class therapeutic peptides and vaccines for human papillomavirus (HPV) infections, malignant tumors, and multidrug-resistant bacterial infections. Zhongao has established two core technology platforms: a Functional Peptide Discovery Platform and a Therapeutic Vaccine R&D Platform. Its lead candidate, ZA001 (F1F3 ointment), is a temperature-sensitive peptide gel containing caerin 1.1 and 1.9 peptides that induces pyroptosis in HPV-infected cells and is currently in Phase 1 clinical development for genital warts and herpes simplex virus infections. The company's pipeline also includes therapeutic vaccines and adjuvants targeting interleukin-10 (IL-10) pathways to overcome immunosuppressive tumor microenvironments.